Dec. 16 at 2:04 PM
H.C. Wainwright⬆️
$STOK's PT to
$50 from
$35 and reiterated at Buy
$BIIB $UCBJY UCBJF
$JAZZ $PRAX
H.C. Wainwright said—Zorevunersen's rigorous propensity-weighted analysis reveals a clinically transformative ~82% seizure reduction and significant cognitive gains, substantially de-risking the Phase 3 EMPEROR study which is powered for far more modest improvements.
With strong KOL validation supporting its use in severe patients despite safety signals, and new data expanding the addressable market to "Atypical Dravet," Stoke offers a scientifically validated "root cause" opportunity with significant regulatory upside.
Therefore, given the data, the potential of zorevunersen for atypical Dravet patients, and the KOL validation, we revisited our PoS assumptions, and our penetration assumptions, which increases our PT from
$35 to
$50.
